Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

dipeptidyl peptidase‐4 inhibitors fotagliptin HbA1c metformin type 2 diabetes Shenzhen Salubris Pharmaceuticals Co., Ltd Shenzhen Science and Technology Program for Undertake the National Science and Technology Major Project CJGJZD20210408091600001 Fotagliptin treatment groups showed a decreasing trend of changes in HbA1c from baseline over the first 24 weeks, with a rapid decrease in the first 12 weeks (Figure 2A ).

also in 47,180 other papers